实体瘤单克隆抗体的输注反应：免疫机制与危险因素

Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors.

作者信息

Chung Christine H, O'Neil Bert H

机构信息

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, School of Medicine, Nashville, Tennessee, USA.

出版信息

Oncology (Williston Park). 2009 Feb;23(2 Suppl 1):14-7.

PMID:19385162

Abstract

The development of monoclonal antibodies targeting various receptors and ligands has been a significant advance in cancer therapy. These monoclonal antibodies are generally well tolerated. A subset of patients, however, experience infusion reactions with symptoms ranging from mild to life-threatening anaphylaxis. The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed.

摘要

靶向各种受体和配体的单克隆抗体的研发是癌症治疗领域的一项重大进展。这些单克隆抗体通常耐受性良好。然而，一部分患者会出现输液反应，症状从轻微到危及生命的过敏反应不等。这些反应的潜在机制尚未得到充分表征。在本综述中，我们将讨论临床风险因素评估的当前发现以及这些输液反应的已知机制。